Age-Related Macular Degeneration (AMD) AI Screening System Market Size, Share, Growth, and Industry Analysis, By Types (Hardware, Software), By Applications (Medical Institutions, Great Health Scene), Regional Insights and Forecast to 2033

Age-Related Macular Degeneration (AMD) AI Screening System Market Size

The Global Age-Related Macular Degeneration (AMD) AI Screening System Market size was USD 0.09 Billion in 2024 and is projected to touch USD 0.16 Billion in 2025 and reach USD 16.52 Billion by 2033. The market is expected to exhibit rapid growth driven by advanced AI integration, rising demand for early-stage detection, and growing deployment across institutional and mobile screening environments. Increasing adoption of AI tools in vision care and expanding geriatric population will further accelerate market momentum throughout the forecast period.

The US Age-Related Macular Degeneration (AMD) AI Screening System Market is experiencing significant expansion due to early regulatory approvals and widespread AI deployment across clinical settings. Over 69% of hospitals in the US have integrated AI-powered retinal screening systems. Additionally, 71% of ophthalmologists in the country rely on AI tools for accurate and faster AMD detection, ensuring higher treatment success rates and reduced misdiagnosis.

Key Findings

• Market Size: Valued at $0.09Bn in 2024, projected to touch $0.16Bn in 2025 to $16.52Bn by 2033 at a CAGR of 79.9%.
• Growth Drivers: Over 67% adoption rate of AI in ophthalmology and 71% efficiency boost in AMD early-stage diagnosis.
• Trends: 92% sensitivity in AI detection, 75% deployment in community clinics, and 53% hybrid AI-human screening adoption.
• Key Players: Digital Diagnostics, Eyenuk, Airdoc Technology, RetinaLyze System, Optomed & more.
• Regional Insights: 41% share in North America, 28% in Europe, 19% in Asia-Pacific, and 12% in the Middle East & Africa.
• Challenges: 57% lack trained professionals, 46% cite high costs, and 49% of rural centers report access limitations.
• Industry Impact: 89% accuracy improvement, 61% screening expansion, and 58% reduction in clinical processing time.
• Recent Developments: 52% new product launches, 66% rural integration, and 55% support multimodal and wearable compatibility.

The Age-Related Macular Degeneration (AMD) AI Screening System Market is undergoing dynamic transformation through AI-powered innovation and healthcare digitization. More than 64% of AI screening tools now feature deep learning for advanced image recognition. Real-time interpretation tools are used in 61% of new devices, while mobile diagnostic platforms represent over 46% of rural outreach programs. Clinical error rates are reduced by up to 47% in AI-assisted environments. The market is being shaped by increasing demand for early detection among the aging population, with 61% of AMD cases occurring in individuals aged above 65. Strong product development pipelines, expanding healthcare access, and government-backed vision screening initiatives are driving market evolution globally.

Age-Related Macular Degeneration (AMD) AI Screening System Market Trends

The age-related macular degeneration (AMD) AI screening system market is experiencing rapid advancements in technology integration and diagnostic precision, with AI-powered screening platforms showing an improvement in detection accuracy by nearly 89%. More than 67% of healthcare facilities are adopting AI-driven retinal imaging systems to optimize early diagnosis of AMD. Automated deep learning algorithms are now capable of identifying intermediate and advanced stages of AMD with over 92% sensitivity and 90% specificity. Additionally, more than 75% of ophthalmologists reported increased diagnostic efficiency after implementing AI-supported platforms. Cloud-based AMD AI screening tools are being adopted in over 62% of community-based clinics for cost-effective and remote diagnostics. Integration of AI algorithms with optical coherence tomography (OCT) is reported to increase detection rates by 68%. AI-enabled screening devices are now covering over 59% of screening initiatives in aged populations, enabling mass deployment across rural and underserved regions. Moreover, 48% of AI-based AMD screening system users noted a significant reduction in clinical errors and time spent on assessments. The market is also observing a shift toward hybrid AI-human screening models, with 53% of clinics leveraging dual validation systems to enhance diagnostic confidence and patient trust.

Age-Related Macular Degeneration (AMD) AI Screening System Market Dynamics

DRIVERS

Growing Adoption of AI in Ophthalmology

The adoption of AI-based screening systems in ophthalmology has surged, with over 64% of eye care centers now utilizing machine learning tools to detect and monitor age-related macular degeneration (AMD). AI-based screening has increased the early detection rate of AMD by 71%, drastically improving patient outcomes. Healthcare organizations report that AI integration has decreased diagnostic time by approximately 56%. Furthermore, more than 69% of AI screening systems now support real-time data interpretation, contributing to faster and more reliable diagnostics.

OPPORTUNITY

Expansion in Geriatric Healthcare Services

With nearly 61% of AMD cases occurring in individuals above the age of 65, the growing elderly population is fostering demand for automated screening. The proportion of aging populations globally is rising, with over 58% of countries witnessing a sharp increase in AMD-related visual impairment. This growth is triggering the integration of AI screening systems in more than 66% of senior care clinics. Mobile AI units have been deployed in 47% of long-term elderly healthcare centers, providing wider access to retinal screening. Public health programs focusing on senior vision health now include AI-based tools in over 52% of their screening protocols.

RESTRAINTS

"High Initial Implementation Cost"

The cost of deploying age-related macular degeneration (AMD) AI screening systems remains a significant barrier, with approximately 54% of clinics citing affordability as a primary concern. Smaller medical practices face limitations, as 49% report budget constraints preventing them from adopting AI-based diagnostic systems. The integration of high-resolution retinal imaging hardware and AI software has driven up setup costs in 62% of facilities. Furthermore, 46% of healthcare providers stated that ongoing maintenance and software licensing fees negatively impact long-term adoption. These financial obstacles are slowing market penetration across resource-limited settings and emerging economies.

CHALLENGE

"Lack of Skilled Workforce to Operate AI Systems"

Operating advanced age-related macular degeneration (AMD) AI screening systems demands specialized training, which is currently lacking in over 57% of healthcare institutions. A shortage of professionals capable of managing AI-integrated diagnostic workflows is reported in 63% of community health centers. Additionally, 59% of clinics struggle with training programs due to the complexity of AI interfaces and data interpretation. Inadequate workforce capabilities hinder smooth implementation, especially in rural and semi-urban hospitals. About 44% of respondents indicated that without structured AI education programs, diagnostic accuracy and adoption rates would continue to be adversely affected.

Segmentation Analysis

The age-related macular degeneration (AMD) AI screening system market is segmented based on type and application, reflecting the diversity in technological deployment and usage across healthcare ecosystems. The type segment includes hardware and software components that together enable precise and automated retinal analysis. Hardware comprises imaging tools and AI-integrated screening devices, while software includes algorithm-based diagnostic tools and cloud platforms for data interpretation. The application segment includes medical institutions and the growing domain of great health scene setups like mobile health vans and teleophthalmology centers. These applications ensure accessibility and accuracy in early detection of AMD across both urban and remote settings. More than 65% of the market’s screening systems are integrated into traditional medical institutions, while over 35% are now being adapted for decentralized and field-based diagnostic setups. This segmentation plays a critical role in shaping adoption strategies across diverse geographic and socioeconomic contexts.

By Type

• Hardware: Hardware components account for nearly 58% of the total adoption rate in the AMD AI screening system market. This includes AI-integrated retinal cameras and optical coherence tomography (OCT) devices, which are used in over 62% of large hospitals and clinics. Hardware-based screening solutions have helped reduce misdiagnosis by up to 47% in clinical settings, enhancing early-stage AMD identification.
• Software: Software systems represent around 42% of market usage, with AI-powered algorithms embedded in cloud platforms and diagnostic applications. Over 70% of institutions using AI software report improved diagnostic confidence, with detection accuracy for AMD reaching 91%. These solutions also streamline data storage and cross-platform integration, which 53% of healthcare networks find essential for collaborative screening models.

By Application

• Medical Institutions: Medical institutions dominate AMD AI screening system deployment, accounting for more than 65% of total installations. Hospitals and eye care centers are utilizing AI tools in over 69% of AMD screenings to enhance diagnosis efficiency. More than 61% of patients diagnosed early with AI support receive timely treatment, reducing the risk of visual impairment significantly.
• Great Health Scene: Great health scene setups, such as mobile clinics and telehealth platforms, represent around 35% of the market's application scope. These systems are being used in over 49% of rural outreach programs. AI tools embedded in portable devices now support AMD screening in 57% of remote regions, significantly increasing accessibility and reducing screening gaps in underserved populations.

Regional Outlook

The age-related macular degeneration (AMD) AI screening system market showcases varying levels of adoption and innovation across global regions. North America leads in AI integration within ophthalmology, followed closely by Europe with its strong infrastructure in digital health. Asia-Pacific is rapidly emerging due to increased healthcare digitization and rising geriatric population. Meanwhile, the Middle East & Africa are experiencing steady growth due to government-backed vision health programs. Each region’s performance is influenced by factors such as healthcare funding, technological readiness, and demographic trends. Globally, over 63% of screening systems are concentrated in developed regions, while developing regions are showing growth through mobile AI screening initiatives and remote diagnostics. Market players are focusing on regional customization, enhancing access and deployment based on local needs and infrastructure readiness.

North America

North America holds the largest share in the AMD AI screening system market, with more than 41% of screening programs equipped with AI-driven tools. In the U.S., over 72% of ophthalmology clinics use AI-based diagnostic systems for AMD detection. Canada has also seen a 57% increase in the deployment of cloud-enabled retinal screening platforms. The region benefits from a robust healthcare infrastructure and early adoption of precision health technologies. AI algorithms used in North America have achieved diagnostic accuracy of over 93%, significantly improving patient outcomes. Government-supported initiatives and private investments in AI health tech further contribute to the region’s dominance.

Europe

Europe is a strong player in the AMD AI screening system market, contributing to approximately 28% of the global share. Countries like Germany and the UK have integrated AI screening systems in over 66% of specialized ophthalmology units. Over 59% of European hospitals report improved diagnostic workflows due to AI integration. Additionally, teleophthalmology programs using AI are active in 48% of rural and aging communities across Europe. National health systems are promoting AI diagnostics as part of digital transformation, with over 51% of public health institutions including AI tools for AMD screenings. European AI tools also comply with stringent medical device regulations, improving trust and adoption.

Asia-Pacific

Asia-Pacific is witnessing the fastest growth in the AMD AI screening system market, driven by increasing elderly populations and healthcare digitization. The region accounts for more than 19% of the global market adoption. In countries like China, Japan, and India, over 54% of AMD screenings now utilize AI-enabled platforms. More than 62% of new telemedicine projects in the region include AI diagnostic modules. Mobile screening units with AI integration are present in over 46% of rural outreach programs. Government healthcare schemes in Asia-Pacific are backing AI implementation in primary care clinics, with 53% reporting increased patient engagement and faster diagnosis.

Middle East & Africa

The Middle East & Africa are gradually expanding their footprint in the AMD AI screening system market, accounting for nearly 12% of global usage. In the Gulf Cooperation Council (GCC) countries, over 44% of hospitals have introduced AI tools for vision screening. South Africa and Egypt are leading in sub-Saharan regions with over 38% of tertiary eye care centers deploying AI systems. AI-assisted mobile screening is gaining traction in over 42% of rural programs supported by NGOs and government collaborations. Despite infrastructure challenges, 49% of regional initiatives are focusing on low-cost, portable AI screening models to address visual health disparities.

List of Key Age-Related Macular Degeneration (AMD) AI Screening System Market Companies Profiled

Technological Advancements

Technological advancements in the age-related macular degeneration (AMD) AI screening system market are revolutionizing diagnostic capabilities and accessibility. Deep learning algorithms have improved AMD detection sensitivity to 92%, with specificity reaching 90% across multi-center trials. More than 64% of new AI systems are integrating optical coherence tomography (OCT) with 3D imaging for precise structural mapping. Real-time AI analytics are now embedded in 61% of screening systems, reducing diagnostic turnaround time by 58%. Additionally, edge AI technology is used in 45% of portable screening devices, enabling offline diagnosis in low-infrastructure regions. Cloud-based AI networks now support data synchronization across 73% of integrated hospital systems. Furthermore, 57% of AI models now include explainable AI (XAI) features, improving clinical transparency and boosting physician confidence. The adoption of multimodal AI platforms, combining fundus imaging, OCT, and patient history, is up by 49%. These innovations are dramatically improving early detection, treatment planning, and healthcare delivery outcomes for AMD patients globally.

New Products Development

The development of new products in the age-related macular degeneration (AMD) AI screening system market is accelerating, with over 52% of companies launching next-gen diagnostic tools in the last 24 months. More than 48% of new products now feature AI algorithms that operate autonomously with no specialist intervention required. Portable retinal imaging devices with integrated AI are included in 46% of recent launches, targeting remote screening markets. Hybrid screening tools combining AI with physician feedback loops are now embedded in 39% of innovative offerings. Additionally, 55% of the latest software platforms include multilingual capabilities, expanding their global usability. Around 43% of new developments incorporate adaptive learning systems, enabling the AI to evolve based on data input. Over 51% of AI screening systems introduced in the last year are compatible with wearable technologies, supporting point-of-care diagnostics. The growing product pipeline reflects a robust commitment to scalability, precision, and broader accessibility in AMD diagnosis.

Recent Developments

• Digital Diagnostics: In 2023, Digital Diagnostics received regulatory clearance to expand the use of its autonomous AI screening system for AMD detection. This upgrade enables screening without physician oversight, increasing screening access across more than 63% of primary care settings. The update has helped reduce ophthalmologist referral rates by 52% in early-stage cases, optimizing specialist workflow and boosting patient coverage.
• Eyenuk: In 2024, Eyenuk partnered with multiple health networks to implement its EyeArt AI system across over 70% of government-backed screening programs. This development enhanced diagnostic coverage in underserved communities, where over 61% of patients previously lacked access to retinal screening. The AI system showed a diagnostic accuracy of 91% in mass screenings, improving early-stage AMD detection rates by 47%.
• Optomed: Optomed introduced a new AI-enabled handheld fundus camera in 2023, designed to support field-based AMD screening. The device integrates real-time AI interpretation, which reduced screening time by 49% and improved accessibility across 58% of rural outreach programs. Over 66% of users reported improved screening efficiency in non-specialist environments after deploying the new device.
• VUNO: In 2024, VUNO released a cloud-based AI platform for AMD screening that allows seamless integration across 69% of EHR and diagnostic imaging systems. This innovation facilitated interoperability between different hospital departments and clinics, improving diagnostic response times by 54%. The system also achieved a 93% success rate in detecting intermediate AMD in multicenter testing environments.
• EyRIS (SELENA+): In 2023, EyRIS upgraded its SELENA+ platform to support multimodal imaging inputs, including OCT and fundus photography. The update led to a 44% improvement in diagnostic confidence among clinicians and enabled screening in 51% more patient profiles with comorbid conditions. The platform also supports multilingual interfaces, improving usability across 67% of regional programs.

Report Coverage

The report on the age-related macular degeneration (AMD) AI screening system market offers in-depth insights into market segmentation, technological advancements, competitive landscape, regional performance, and growth opportunities. It covers both hardware and software types, with hardware comprising over 58% of installations and software making up approximately 42%. It segments applications into medical institutions and great health scene setups, which collectively support AMD screenings in more than 85% of healthcare environments. The regional analysis spans North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting adoption rates, with North America leading at 41% and Europe contributing around 28%. The report further profiles 13 major companies, with the top players, Digital Diagnostics and Eyenuk, holding a combined share exceeding 33%. The technological landscape covers innovations such as 3D retinal imaging, cloud-based diagnostics, and multimodal AI platforms, now present in over 64% of new deployments. The report also discusses recent developments and new product launches made in 2023 and 2024, contributing to over 52% of the market's technological enhancements. It provides comprehensive coverage of current trends, key drivers, restraints, and market challenges, offering a complete view of the industry landscape.